Kalydeco Web Header v2

Campaign for Kalydeco

Kalydeco is an important treatment for many people with cystic fibrosis, and the evidence behind it is strong and unequivocal. New Zealand is the only country in the OCED (with a high incidence of CF) that does not fund Kalydeco for people who have the G551D gene.

Cystic Fibrosis NZ and Kalydeco for Kiwis are running a joint campaign to get Kalydeco publicly funded in NZ.


Donate to campaign button


View advocacy timeline


About the campaign

Cystic Fibrosis NZ and Kalydeco for Kiwis are running a joint campaign to get Kalydeco publicly funded in NZ.

Early September PHARMAC called for applications from suppliers of medicines for rare disorders. From the applications, we expect PHARMAC to announce funding for medicines for rare disorders. Vertex, Kalydeco's manufacturer, put in an application for Kalydeco.

We'll be talking with politicians (including the Minister of Health) and PHARMAC about why it's important to fund Kalydeco. But we think a key part is showing public support for funding Kalydeco. This is why the awareness campaign is so important. It means we need to go out in the community and get as many people as possible participating in the campaign and showing their support.

We expect PHARMAC to announce their decision early 2019, so we'll be running the campaign from late Sept/early October until we hear the decision. We're going push as hard as possible to get Kalydeco funded through this process with PHARMAC, but if the decision is not what we want we're not going to stop there, we'll keep pushing until we see Kalydeco publicly funded. 

 

About Kalydeco

Kalydeco is a type of medicine used to treat a strand of cystic fibrosis called G551D.

Kalydeco is the first medication that fixes the underlying cystic fibrosis defect, essentially turning off cystic fibrosis. Kalydeco represents a major breakthrough in cystic fibrosis research; current medications only treat the symptoms.

“Kalydeco has been hailed as a miracle drug – and with good reason. It has massive health benefits. Current life expectancy for those with cystic fibrosis is 37 years, but this drastically improves with Kalydeco. Every day that Kalydeco remains unfunded in New Zealand, irreversible lung damage is occurring” says Cass Byrnes, Cystic Fibrosis NZ's Medical Spokesperson.

The evidence backing Kalydeco is unequivocal. New Zealand is the only country in the OECD (with a significant cystic fibrosis population) that has not funded Kalydeco for those with G551D cystic fibrosis.

Read full press release

How you can take action

We need as many people as possible to join and help us get Kalydeco funded.

We’ve launched a public awareness campaign to raise awareness of Kalydeco and we’re encouraging people to write to PHARMAC in support of the application for Kalydeco. To raise awareness we're also asking people to help spread the word in any way they can in their community, for example meeting with their electorate MP, writing an article for the local paper, talking to local organisations etc.

You can help by:  

  • Joining CFNZ and Kalydeco for Kiwis on Facebook
  • Holding, or participating in, a local event
  • Writing to PHARMAC
  • Meeting with your local electorate MP
  • Talking with your friends and family about the issue
  • Posting information on your social media feed
  • Writing a letter to your local paper or drafting an article 
  • Participating in the sticker campaign.

We've put together letter templates, key points and other hints and tips to help you out. This advocacy toolkit is designed to help you take action. 

Advocacy Toolkit Button


If you have any feedback about the toolkit, or other things that would help you, let us know!

 

023 CF Finals

Know your gene

As more precision medicines are developed that target specific faulty genes, it’s becoming increasingly important to know your genetic typing. From the PORT CF data we hold, we can see that not all CFers know their genetic type. 

Jan Tate, CF Nurse at Starship, recommends "I encourage all CFers to ask their consultants for another blood test when they have their annual blood taken. This can be done through the clinic you attend. Most adults will have had their genes tested when they were infants when the CF gene panel was very limited. Since then many more CF genes have been identified. The CF panel has 50 common CF genes and the lab is now able to identify most CF genes". 

Knowing the genes you carry could open up opportunities for different or better treatments as time progresses. If you have any questions please contact your fieldworker or CF nurse.

Join the sticker campaign!

Show your support by posting a photo of a campaign sticker on Facebook and tagging CFNZ and Kalydeco for Kiwis. The aim is to get the sticker in the coolest, most unique place!


Order Stickers Button

Key campaign messages

  • We want to see Kalydeco publicly funded for New Zealanders with G551D Cystic Fibrosis aged 2 years and older.

  • Kalydeco is the first medication that fixes the underlying cystic fibrosis defect, essentially turning off cystic fibrosis. Kalydeco represents a major breakthrough in cystic fibrosis research; current medications only treat the symptoms. Every day that Kalydeco remains unfunded in New Zealand, irreversible lung damage is occurring.

  • Kalydeco works.  It is a proven treatment, that is backed up by robust data and a universal consensus that it is hugely beneficial for those with G551D cystic fibrosis.

  • NZ is the only country in the OECD (with a significant cystic fibrosis population) that has not funded Kalydeco for those with G551D cystic fibrosis. 

  • Kalydeco alleviates many of the symptoms and issues associated with cystic fibrosis.  It is preventative as it treats the underlying cause of cystic fibrosis, preventing symptoms developing in the first place.

  • There are societal and economic reasons for funding Kalydeco. The cost of Kalydeco is drastically offset through a reduction in health costs. Kalydeco prevents complications that require costly treatment. For example, the need for lung transplants is likely to be greatly reduced, as lung damage is effectively halted while on Kalydeco. Furthermore, there are important social and societal benefits from people with cystic fibrosis needing less time off work, away from school, away from their families and so forth. 

Download the Kalydeco advocacy toolkit
012 CF Finals

Campaign logo

We have a special 'Kalydeco for Kiwis' logo that you are welcome to download and share around!

If you'd like a high res version or AI file please get in touch with Laura.

U lezY2g

Download campaign logo